A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Public ClinicalTrials.gov record NCT07285655. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.
Study identification
- NCT ID
- NCT07285655
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 344 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2026 (Actual)
- Primary completion
- Jul 2029 (Estimated)
- Completion
- Dec 2031 (Estimated)
- Last update posted
- Oct 14, 2026
2026 – 2031
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dignity Health - St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | Recruiting |
| Arizona Pulmonary Specialists, Ltd. | Scottsdale | Arizona | 85258 | Recruiting |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095-1690 | Recruiting |
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
| University of Colorado Hospital | Aurora | Colorado | 80045 | Recruiting |
| National Jewish Hospital | Denver | Colorado | 80206 | Recruiting |
| Tampa General Hospital | Tampa | Florida | 33606 | Recruiting |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| St. Vincent Cardiovascular Research Institute | Indianapolis | Indiana | 46260 | Recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| University of Rochester Medical Center | Rochester | New York | 14642 | Recruiting |
| Summit Health | Bend | Oregon | 97701 | Recruiting |
| Medical University of South Carolina- Nexus Research Clinic | Charleston | South Carolina | 29425 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07285655, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07285655 live on ClinicalTrials.gov.